US Bancorp DE Has $5.56 Million Stock Position in Revvity Inc. $RVTY

US Bancorp DE lowered its holdings in Revvity Inc. (NYSE:RVTY) by 3.6% during the second quarter, HoldingsChannel.com reports. The institutional investor owned 57,445 shares of the company’s stock after selling 2,148 shares during the period. US Bancorp DE’s holdings in Revvity were worth $5,556,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its holdings in shares of Revvity by 8.5% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 22,515,711 shares of the company’s stock worth $2,382,163,000 after purchasing an additional 1,754,403 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Revvity by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 14,382,849 shares of the company’s stock worth $1,521,705,000 after purchasing an additional 92,638 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Revvity by 25.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,563,911 shares of the company’s stock worth $1,011,863,000 after purchasing an additional 1,932,314 shares in the last quarter. EdgePoint Investment Group Inc. grew its holdings in shares of Revvity by 32.1% during the 1st quarter. EdgePoint Investment Group Inc. now owns 5,360,847 shares of the company’s stock worth $567,178,000 after purchasing an additional 1,302,616 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in shares of Revvity by 1.8% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,444,645 shares of the company’s stock worth $364,443,000 after purchasing an additional 62,307 shares in the last quarter. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Price Performance

Revvity stock opened at $88.36 on Monday. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.33 and a quick ratio of 2.75. The company has a market capitalization of $10.26 billion, a PE ratio of 37.44, a price-to-earnings-growth ratio of 2.94 and a beta of 0.98. Revvity Inc. has a one year low of $81.36 and a one year high of $129.50. The business has a 50 day simple moving average of $88.08 and a 200 day simple moving average of $92.73.

Revvity (NYSE:RVTY) last posted its earnings results on Monday, July 28th. The company reported $1.18 EPS for the quarter, topping the consensus estimate of $1.14 by $0.04. The business had revenue of $720.28 million during the quarter, compared to the consensus estimate of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.Revvity’s revenue was up 4.1% on a year-over-year basis. During the same quarter last year, the company earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, sell-side analysts forecast that Revvity Inc. will post 4.94 EPS for the current fiscal year.

Revvity Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Shareholders of record on Friday, October 17th will be paid a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a yield of 0.3%. Revvity’s payout ratio is currently 11.86%.

Analysts Set New Price Targets

RVTY has been the topic of several recent research reports. Stifel Nicolaus decreased their price objective on Revvity from $120.00 to $110.00 and set a “hold” rating on the stock in a report on Tuesday, July 29th. Wall Street Zen lowered Revvity from a “buy” rating to a “hold” rating in a report on Sunday, August 3rd. Weiss Ratings lowered Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, October 8th. Barclays decreased their price objective on Revvity from $110.00 to $100.00 and set an “overweight” rating on the stock in a report on Thursday, October 2nd. Finally, Bank of America decreased their price objective on Revvity from $110.00 to $99.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. Ten equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $117.93.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.